Meet David Kendall, Chief Scientific Officer, PharmNovo
As PharmNovo advances into phase II clinical studies with drug candidate PN6047, Chief Scientific Officer David Kendall plays a crucial role in the company’s success. With three decades of expertise bridging academia and industry, his visionary leadership and groundbreaking ideas are instrumental.
David Kendall's academic journey, including a pharmacy degree and a PhD in Neuropharmacology, reflects his exceptional credentials. His early industrial pharmacology experience, coupled with academic tenures at esteemed institutions like the Universities of Texas and Leicester, positions him as a leader in his field.
Until August 2015, he was a Professor of Pharmacology and former Head of Biomedical Sciences at the University of Nottingham Medical School.
In 2010, David Kendall joined PharmNovo, and five years later he assumed the role of Chief Scientific Officer.
“I met and worked alongside Dr Bengt von Mentzer when we were both postdoctoral researchers at the University of Leicester. When he told me that he was setting up PharmNovo, I thought that it was a very exciting venture with a strong underlying pharmacological basis and I was delighted to use my resources at the University of Nottingham to move things forward”, says David Kendall.
Under David Kendall's guidance, PharmNovo has built long-standing collaborations with scientists at the University of Bristol (UK), the University of Pecz (HU), the University of Michigan, Washington University and several other leading research centres, as well as an international network of leading pain experts and advisors.
“Drug discovery is a multifactorial business demanding expert input from a wide range of scientists with specialist skills. Collaborations between academic groups and industry blend cutting-edge technology with pharma experience and know-how and are essential in staying at the forefront of neuropathic pain research and development.”
David Kendall has during his years at PharmNovo played a pivotal role in guiding and overseeing PharmNovo’s scientific and research endeavours.
“My background is in basic pharmacology, researching the mechanisms of action of drugs acting on the nervous system, but my passion is applying such knowledge to the invention of practical medicines. By introducing the concept of biased signalling to the study of novel delta opioid receptor agonists, we have developed PN6047 which has the potential to deliver significant benefit to neuropathic pain sufferers with none of the unwanted effects of existing, less sophisticated, therapies. “
Entering clinical phase II proof-of-concept studies, David Kendall's mission is to ensure that the trials are designed to generate robust data to support the drug's safety and efficacy.
Meet David Kendall, Chief Scientific Officer, PharmNovo
As PharmNovo advances into phase II clinical studies with drug candidate PN6047, Chief Scientific Officer David Kendall plays a crucial role in the company’s success. With three decades of expertise bridging academia and industry, his visionary leadership and groundbreaking ideas are instrumental.
David Kendall's academic journey, including a pharmacy degree and a PhD in Neuropharmacology, reflects his exceptional credentials. His early industrial pharmacology experience, coupled with academic tenures at esteemed institutions like the Universities of Texas and Leicester, positions him as a leader in his field.
Until August 2015, he was a Professor of Pharmacology and former Head of Biomedical Sciences at the University of Nottingham Medical School.
In 2010, David Kendall joined PharmNovo, and five years later he assumed the role of Chief Scientific Officer.
“I met and worked alongside Dr Bengt von Mentzer when we were both postdoctoral researchers at the University of Leicester. When he told me that he was setting up PharmNovo, I thought that it was a very exciting venture with a strong underlying pharmacological basis and I was delighted to use my resources at the University of Nottingham to move things forward”, says David Kendall.
Under David Kendall's guidance, PharmNovo has built long-standing collaborations with scientists at the University of Bristol (UK), the University of Pecz (HU), the University of Michigan, Washington University and several other leading research centres, as well as an international network of leading pain experts and advisors.
“Drug discovery is a multifactorial business demanding expert input from a wide range of scientists with specialist skills. Collaborations between academic groups and industry blend cutting-edge technology with pharma experience and know-how and are essential in staying at the forefront of neuropathic pain research and development.”
David Kendall has during his years at PharmNovo played a pivotal role in guiding and overseeing PharmNovo’s scientific and research endeavours.
“My background is in basic pharmacology, researching the mechanisms of action of drugs acting on the nervous system, but my passion is applying such knowledge to the invention of practical medicines. By introducing the concept of biased signalling to the study of novel delta opioid receptor agonists, we have developed PN6047 which has the potential to deliver significant benefit to neuropathic pain sufferers with none of the unwanted effects of existing, less sophisticated, therapies. “
Entering clinical phase II proof-of-concept studies, David Kendall's mission is to ensure that the trials are designed to generate robust data to support the drug's safety and efficacy.
Latest news
View all
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more